Proton-driven transformable nanovaccine for cancer immunotherapy.

Area of Science:

• Biotechnology
• Immunology
• Materials Science

Background:

• Cancer vaccines aim to improve treatment but face challenges like endosomal trapping and low tumor antigen immunogenicity.
• Efficient delivery of tumor antigens is crucial for effective cancer vaccination strategies.

Purpose of the Study:

• To develop a proton-driven nanotransformer-based vaccine for enhanced cancer immunotherapy.
• To overcome limitations of endosomal trapping and improve antigen delivery and immunogenicity.

Main Methods:

• A polymer-peptide conjugate nanotransformer loaded with antigenic peptide was designed.
• The nanotransformer undergoes a pH-dependent morphological transformation from nanospheres to nanosheets within acidic endosomes.
• This transformation facilitates endosomal escape and direct cytoplasmic delivery of antigenic peptides.

Main Results:

• The nanotransformer-based vaccine induced a strong immune response with minimal systemic toxicity.
• Morphological transformation mechanically disrupted endosomal membranes, enabling efficient antigen delivery.
• Significant inhibition of tumor growth was observed in B16F10-OVA and HPV-E6/E7 mouse models.
• Combination therapy with anti-PD-L1 antibodies led to prolonged survival and complete tumor regression in a subset of mice.

Conclusions:

• The proton-driven nanotransformer offers a robust and safe strategy for cancer immunotherapy.
• This nanovaccine technology effectively enhances tumor immunity by overcoming antigen delivery barriers.